Vulvovaginal Atrophy: Clinical Trials

10 trials for Vulvovaginal Atrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 withdrawn, 1 terminated. 10 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 6, Withdrawn 3, Terminated 1
Phase 11Completed 1

Follow Vulvovaginal Atrophy: new trials by email Literature Review of Vulvovaginal Atrophy trials Research Report on Vulvovaginal Atrophy

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women
IVR Dose 1, IVR Dose 2 - Vulvovaginal Atrophy, Vasomotor Symptoms
Phase 1 / Phase 2CompletedDaré Bioscience, Inc.212022-04-112024-10-31
Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women.
Estrogen vaginal cream group (group A), Photobiomodutation group (group B) - Vulvovaginal Atrophy
Phase 2WithdrawnUniversity of Nove de Julho2020-12-152023-06-29
Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA
WO533 - Vulvovaginal Atrophy
Phase 2CompletedDr. August Wolff GmbH & Co. KG Arzneimittel432020-01-272021-12-23
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
Carbon Dioxide Fractional Laser, Questionnaire Administration - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Phase 2WithdrawnMayo Clinic2018-09-102023-01-06
Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment
5% sinecatechins ointment, Placebo, 10% sinecatechins ointment - Sexual Pain Disorders, Postmenopausal Symptoms
Phase 2TerminatedGTO Pharmaceutical, LLC322018-08-302022-07-27
Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy
Vaginal progesterone, Placebo - Atrophic Vaginitis, Menopause
Phase 2WithdrawnMount Sinai Hospital, Canada2016-12-012024-03-20
Visnadine, Prenylflavonoids and Bovine Colostrum to Treat Vulvovaginal Atrophy in Postmenopausal Women
Visnadine, prenylflavonoids and bovine colostrum - Vulvovaginal Atrophy, Menopause
Phase 2CompletedUniversity of Messina542016-12-012020-03-25
Study to Evaluate Efficacy of Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy Symptoms
Oxytocin 400 IU vaginal gel, Placebo - Vulvovaginal Atrophy
Phase 2CompletedPepTonic Medical AB2022016-05-032020-11-16
A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy
Estradiol Vaginal Capsule (EVC), Placebo - Vulvovaginal Atrophy, Menopause
Phase 2CompletedWarner Chilcott2032016-02-152017-08-23
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
Estradiol, placebo - Menopause, Vulvovaginal Atrophy
Phase 2CompletedTherapeuticsMD502013-07-012015-12-14

Narrower conditions

Dyspareunia (4)  ·  Atrophic Vaginitis (1)  ·  Breast Carcinoma In Situ (1)  ·  Sexual Dysfunctions, Psychological (1)  ·  Vulvodynia (1)

Broader conditions

Female Urogenital Diseases (5)  ·  Female Urogenital Diseases and Pregnancy Complications (5)  ·  Genital Diseases (5)  ·  Genital Diseases, Female (5)  ·  Urogenital Diseases (5)  ·  Genital Diseases, Male (4)  ·  Male Urogenital Diseases (4)  ·  Mental Disorders (4)  ·  Sexual Dysfunction, Physiological (4)  ·  Sexual Dysfunctions, Psychological (3)  ·  Breast Diseases (1)  ·  Breast Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma in Situ (1)  ·  Neoplasms (1)

Interventions

Estradiol (1)  ·  Oxytocin (1)  ·  Petrolatum (1)  ·  Vaginal Creams, Foams, and Jellies (1)  ·  polyphenon E (1)  ·  visnadin (1)

Sponsors

DarĂ© Bioscience, Inc. (1)  ·  Dr. August Wolff GmbH & Co. KG Arzneimittel (1)  ·  GTO Pharmaceutical, LLC (1)  ·  Mayo Clinic (1)  ·  Mount Sinai Hospital, Canada (1)  ·  PepTonic Medical AB (1)  ·  TherapeuticsMD (1)  ·  University of Messina (1)  ·  University of Nove de Julho (1)  ·  Warner Chilcott (1)

Countries

United States (3)  ·  Australia (1)  ·  Canada (1)  ·  Germany (1)  ·  Sweden (1)

Top investigators

Aino Fianu Jonasson, MD (1)  ·  Kirstin Deuble-Bente, MD (1)  ·  Lila Nachtigall, M.D. (1)  ·  Salvatore Giovanni Vitale, M.D. (1)  ·  Saranya Chumsri (1)  ·  Shelli Graham, PhD (1)  ·  Vilma Sniukiene, MD (1)  ·  Wendy L Wolfman, MD, FRCSC (1)

Results publications

PMID 36787527, PMID 37339390, PMID 37619252, PMID 37625088

NIH funding

2016 (1), 2019 (1)